疑似艰难梭菌感染患者毒素EIA阳性的临床意义:系统综述与荟萃分析
两组全因死亡率、归因死亡率、暴发性CDI、影像学证据、总并发症、结肠切除术及ICU入住率均无显著差异,但NAAT+/EIA-患者复发和重症CDI风险显著更低。毒素结果不能确诊或排除CDI,是否治疗NAAT+/EIA-患者应基于临床表现而非毒素结果。
要点
- NAAT+/EIA-与NAAT+/EIA+患者死亡率及CDI相关并发症风险相似。
- NAAT+/EIA-患者复发和重症CDI风险显著低于NAAT+/EIA+患者。
- 毒素结果不应作为是否治疗CDI的决定因素,应基于临床评估。
核心结论
- NAAT+/EIA-患者复发率和重症CDI风险低于NAAT+/EIA+患者,但CDI相关并发症和死亡率风险相当。
- 毒素结果不能确诊或排除CDI,是否治疗症状性NAAT+/EIA-患者应基于临床表现而非毒素结果。
主要发现
- 全因死亡率RR 0.96(95% CI 0.80-1.15)、归因死亡率RR 0.61(95% CI 0.20-1.91)、暴发性CDI RR 0.83(95% CI 0.57-1.20)、影像学证据RR 0.87(95% CI 0.65-1.16)、总CDI并发症RR 0.95(95% CI 0.59-1.53)、结肠切除术RR 0.78(95% CI 0.34-1.79)、ICU入住RR 1.04(95% CI 0.84-1.30)在两组间均无显著差异。
- NAAT+/EIA-患者复发CDI率(RR 0.62,95% CI 0.50-0.77)和重症CDI率(RR 0.74,95% CI 0.63-0.88)显著低于NAAT+/EIA+患者。
- NAAT+/EIA-患者接受CDI抗生素治疗的合并患病率为73.4%(合并比例0.72,95% CI 0.52-0.88)。
关键数值与推荐
- 全因死亡率RR 0.96(95% CI 0.80-1.15),归因死亡率RR 0.61(95% CI 0.20-1.91),暴发性CDI RR 0.83(95% CI 0.57-1.20)。
- 复发CDI RR 0.62(95% CI 0.50-0.77),重症CDI RR 0.74(95% CI 0.63-0.88)。
- NAAT+/EIA-患者接受CDI抗生素治疗的合并患病率73.4%(95% CI 0.52-0.88)。
临床怎么用
- 毒素检测可帮助预测CDI复发或重症感染的可能性,但不应作为是否给予CDI治疗的 determining factor。
- 对症状性NAAT+/EIA-患者是否治疗应基于临床评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The laboratory diagnosis of Clostridioides difficile infection (CDI) is controversial. Nucleic acid amplification tests (NAAT) and toxin enzyme immunoassays (EIA) are most widely used, often in combination. However, the interpretation of a positive NAAT and negative toxin immunoassay (NAAT+/EIA-) is uncertain. PubMed and EMBASE were searched for studies reporting clinical outcomes in NAAT+/EIA- versus NAAT+/EIA+ patients. Forty-six studies comprising 33,959 patients were included in this meta-analysis. All-cause mortality (RR 0.96, 95% CI 0.80-1.15), attributable mortality (RR 0.61, 95% CI 0.20-1.91), fulminant CDI (RR 0.83, 95% CI 0.57-1.20), radiographic evidence of CDI (RR 0.87, 95% CI 0.65-1.16), total CDI complications (RR 0.95, 95% CI 0.59-1.53), colectomies (RR 0.78, 95% CI 0.34-1.79), and ICU admission (RR 1.04, 95% CI 0.84-1.30) did not significantly differ between NAAT+/EIA- and NAAT+/EIA+ patients. However, rates of recurrent (RR 0.62, 95% CI 0.50-0.77) or severe (RR 0.74, 95% CI 0.63-0.88) CDI were significantly lower in NAAT+/EIA- patients than in NAAT+/EIA+ patients. The pooled prevalence of NAAT+/EIA- patients who were treated with antibiotics for CDI was 73.4% (pooled proportion 0.72, 95% CI 0.52-0.88). NAAT+/EIA- patients have lower rates of recurrence and are at reduced risk for severe CDI compared with NAAT+/EIA+ patients but have a risk of CDI-related complications and mortality comparable to that of NAAT+/EIA+ patients. Toxin results cannot rule in or rule out CDI, and the decision whether to treat symptomatic NAAT+/EIA- patients for CDI should be based on clinical presentation and not on the toxin result.IMPORTANCEClostridioides difficile infection (CDI) is a common cause of healthcare-associated infections and the leading cause of antibiotic-associated diarrhea. However, the laboratory diagnosis of CDI, primarily done by nucleic acid amplification test (NAAT) and enzyme immunoassay (EIA), is controversial, especially in patients who test positive by NAAT but negative by EIA. In this systematic review, we compared the clinical outcomes of NAAT+/EIA- versus NAAT+/EIA+ patients and found that the two groups have similar risk of mortality and CDI-related complications. However, NAAT+/EIA- patients had significantly lower rates of recurrence and severe CDI than NAAT+/EIA+ patients, and most NAAT+/EIA- patients received CDI therapy. Toxin testing can help to predict the likelihood of CDI recurrence or severe infection, but the toxin result should not be a determining factor in the administration of CDI therapy. The decision on whether to treat NAAT+/EIA- patients should be based on clinical assessment.
引用
- Tansarli GS, Falagas ME, Fang FC, et al. Clinical significance of toxin EIA positivity in patients with suspected Clostridioides difficile infection: systematic review and meta-analysis. J Clin Microbiol. 2024. PMID: 39665542. doi:10.1128/jcm.00977-24
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。